FAK/SRC通路适应性反馈信号促进KRAS G12C抑制剂耐药
该临床前研究通过高通量药物筛选和临床前模型,探索增强KRAS G12C抑制剂疗效并防止耐药出现的联合策略。研究发现FAK/SRC通路是KRAS抑制剂治疗触发多种受体酪氨酸激酶和整合素反馈激活RAS/MAPK和AKT通路的关键介质,FAK和SRC抑制剂在临床前模型中与KRAS抑制剂协同,并使获得性耐药细胞对sotorasib重新敏感,FAK药理学阻断增强了KRAS抑制剂的抗肿瘤活性。
要点
- FAK/SRC通路介导KRAS G12C抑制剂治疗后的适应性反馈激活。
- FAK和SRC抑制剂在临床前模型中与KRAS抑制剂协同。
- FAK/SRC抑制剂可逆转获得性KRAS抑制剂耐药。
核心结论
- FAK/SRC抑制剂具有减轻KRAS抑制诱导的适应性信号并增强KRAS抑制剂临床活性的治疗潜力。
研究设计与样本
- 采用高通量药物筛选方法和临床前模型进行研究。
主要发现
- FAK/SRC通路是KRAS抑制剂治疗触发多种受体酪氨酸激酶和整合素反馈激活RAS/MAPK和AKT通路的关键介质。
- FAK和SRC抑制剂在临床前模型中与KRAS抑制剂协同。
- FAK/SRC抑制剂使获得性KRAS抑制剂耐药的细胞对sotorasib重新敏感。
- 在异种移植模型中,FAK的药理学阻断增强了KRAS抑制剂的抗肿瘤活性。
临床怎么用
- 临床前数据提示FAK/SRC抑制剂联合KRAS G12C抑制剂可能增强疗效并克服耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Allele-specific KRAS inhibitors, such as the KRASG12C inhibitors sotorasib and adagrasib, have demonstrated clinical activity as monotherapy, but adaptive signaling in response to KRAS pathway inhibition can promote resistance and limit the efficacy of these drugs. More effective combinatorial strategies are sorely needed to enhance efficacy and improve clinical outcomes in this patient population. METHODS: Using a high-throughput drug-screening approach and preclinical models, we investigated effective combinatorial strategies that enhance the efficacy of KRAS G12C inhibitors and prevent the emergence of resistance. RESULTS: We identified that the focal adhesion kinase (FAK)/SRC pathway is a key mediator of the feedback activation of RAS/MAPK and AKT pathways triggered by the activation of multiple receptor tyrosine kinases and integrins in response to KRAS inhibitor treatment. Consistent with this observation, FAK and SRC inhibitors were found to synergize with KRAS inhibitors in preclinical models, and FAK/SRC inhibitors resensitized cells with acquired KRAS inhibitor resistance to sotorasib. Using xenograft models, we observed that pharmacologic blockade of FAK enhanced the antitumor activity of KRAS inhibitors. CONCLUSION: These data highlight the therapeutic potential of FAK/SRC inhibitors to mitigate adaptive signaling induced by KRAS inhibition and enhance the clinical activity of KRAS inhibitors.
引用
- Udagawa H, Shibata Y, Nilsson MB, et al. Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance. J Thorac Oncol. 2026. PMID: 42336204. doi:10.1016/j.jtho.2026.103991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。